Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in the upcoming Oppenheimer Healthcare MedTech & Services Conference, being held virtually.

Management is scheduled to participate on Wednesday, March 13, 2024, at 12:00pm ET and will hold one-on-one meetings following. Interested parties may access a live and recorded webcast of the presentation on the "Investor Relations" section of the company's website at www.senseonics.com.

About Senseonics

Senseonics Holdings, Inc. ("Senseonics") is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology. Senseonics' CGM system Eversense(R) E3 includes a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user's smartphone.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240306655647/en/

SOURCE: Senseonics Holdings, Inc.

<img alt="" src="https://cts.businesswire.com/ct/CT?id=bwnews&sty=20240306655647r1&sid=cmtx6&distro=nx&lang=en" style="width:0;height:0" />

Senseonics Investor Contact Philip Taylor Gilmartin Group 415-937-5406 Investors@senseonics.com

COMTEX_448839464/1006/2024-03-06T08:05:02